Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study

Схожі ресурси

• Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study
  за авторством: Guillaume Cartron, та інші
  Опубліковано: (2018-08-01)
• Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia
  за авторством: Thomas Elter, та інші
  Опубліковано: (2009-01-01)
• Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
  за авторством: William Y. K. Hwang, та інші
  Опубліковано: (2009-01-01)
• Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK
  за авторством: M Hoyle, та інші
  Опубліковано: (2011-05-01)
• Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)
  за авторством: Anne Quinquenel, та інші
  Опубліковано: (2020-10-01)